Stimulation of osteoclastic bone resorption in a model of glycerol-induced acute renal failure: evidence for a parathyroid hormone-independent mechanism

Bone ◽  
2002 ◽  
Vol 31 (4) ◽  
pp. 488-491 ◽  
Author(s):  
A Gal-Moscovici ◽  
P Scherzer ◽  
D Rubinger ◽  
R Weiss ◽  
M Dranitzki-Elhalel ◽  
...  
1982 ◽  
Vol 243 (6) ◽  
pp. E499-E504
Author(s):  
N. S. Krieger ◽  
P. H. Stern

The cardiotonic agent amrinone has been postulated to directly affect Na-Ca exchange. Because stimulated bone resorption has been proposed to require Na-Ca exchange, we examined the effects of amrinone on bone. Amrinone inhibited release of Ca from neonatal mouse calvaria in organ culture stimulated by parathyroid hormone (PTH), 1,25-dihydroxyvitamin d3, or prostaglandin E2. Inhibition was dose dependent and maximal at 2 X 10(-4) M. The effect of amrinone differed from the inhibitory effects of calcitonin, ouabain, or nigericin in that 1) 6-h exposure to amrinone alone prevented the effect of subsequently added PTH; 2) amrinone was only partially effective if added after resorption was initiated by 24-h treatment with PTH; 3) coincubation with amrinone and PTH during the first 48 h of culture allowed for a response to PTH after amrinone was removed; no such protection by a stimulator occurred with ouabain or nigericin. Also submaximal concentrations of amrinone plus calcitonin, ouabain, or nigericin gave greater than additive inhibition of Ca release. Amrinone had no effect on basal bone cAMP or on the acute stimulation of cAMP by PTH. The results suggest that amrinone could have a more direct interaction with the pathway involved in stimulated bone resorption than the other inhibitors.


1978 ◽  
Vol 6 (4) ◽  
pp. 342-349 ◽  
Author(s):  
A. M. S. Black

Thirteen of sixteen patients with acute renal failure and requiring respiratory and other supportive treatment in an intensive care area became hypercalcaemic whilst still receiving haemodialysis. Results of calcium, phosphate and parathyroid hormone estimations are presented and their disturbances in acute renal failure are discussed.


Nephron ◽  
1978 ◽  
Vol 20 (4) ◽  
pp. 196-202 ◽  
Author(s):  
M. Fuss ◽  
J. Bagon ◽  
E. Dupont ◽  
T. Manderlier ◽  
H. Brauman ◽  
...  

1992 ◽  
Vol 183 (3) ◽  
pp. 1153-1158 ◽  
Author(s):  
Bridget E. Bax ◽  
A.S.M.Towhidul Alam ◽  
Bashab Banerji ◽  
Christopher M.R. Bax ◽  
Peter J.R. Bevis ◽  
...  

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Marc N. Wein ◽  
Yanke Liang ◽  
Olga Goransson ◽  
Thomas B. Sundberg ◽  
Jinhua Wang ◽  
...  

Abstract Parathyroid hormone (PTH) activates receptors on osteocytes to orchestrate bone formation and resorption. Here we show that PTH inhibition of SOST (sclerostin), a WNT antagonist, requires HDAC4 and HDAC5, whereas PTH stimulation of RANKL, a stimulator of bone resorption, requires CRTC2. Salt inducible kinases (SIKs) control subcellular localization of HDAC4/5 and CRTC2. PTH regulates both HDAC4/5 and CRTC2 localization via phosphorylation and inhibition of SIK2. Like PTH, new small molecule SIK inhibitors cause decreased phosphorylation and increased nuclear translocation of HDAC4/5 and CRTC2. SIK inhibition mimics many of the effects of PTH in osteocytes as assessed by RNA-seq in cultured osteocytes and following in vivo administration. Once daily treatment with the small molecule SIK inhibitor YKL-05-099 increases bone formation and bone mass. Therefore, a major arm of PTH signalling in osteocytes involves SIK inhibition, and small molecule SIK inhibitors may be applied therapeutically to mimic skeletal effects of PTH.


Sign in / Sign up

Export Citation Format

Share Document